Hilleman Lab to invest Rs 300 crore to develop vaccines

"We are spending around Rs 300 crore over the next 4-5 years to develop low-cost vaccines. We are developing vaccines to treat rotavirus, cholera and meningitis," Hilleman CEO Davinder Gill told PTI here.
Source: The Economic Times - Category: Consumer Health News Source Type: news